Loeys-Dietz syndrome (LDS) is an inherited connective tissue disorder characterized by arterial aneurysms and dissections, vascular tortuosity, and multisystemic involvement. It is associated with heterozygous pathogenic variants in TGFBR1, TGFBR2, SMAD3, or TGFB2 and follows an autosomal dominant pattern. These alterations dysregulate the transforming growth factor beta (TGF-β) pathway and particularly weaken the arterial wall.
Loeys-Dietz Syndrome
TGFBR1 and TGFBR2 encode transmembrane receptors with serine/threonine kinase activity; TGFB2 encodes one of their ligands and SMAD3 an intracellular mediator. The pathway regulates development, vascular smooth muscle, and extracellular matrix turnover. Pathogenic variants alter different levels of the TGF-β pathway. Although some changes reduce receptor or mediator activity, compensatory increases in TGF-β-dependent signaling may exist in affected tissues. This causes fragmentation of elastic fibers and degeneration of the arterial media layer, favoring aneurysms and dissections. Inheritance is autosomal dominant, and many cases are due to de novo variants. The exact prevalence is unknown, although it is estimated at around 1 in 50,000 people. No predominant founder effect has been established, and clinical expression is highly variable, even within the same family.
Symptoms
Manifestations can appear from birth to adulthood. The main involvement includes aortic dilation, aneurysms, dissections, and generalized arterial tortuosity. Hypertelorism, bifid uvula or cleft palate, craniosynostosis, pectus, scoliosis, arachnodactyly, clubfoot, hyperlaxity or contractures, and cervical instability can also be observed. Thin skin, bruising, abnormal scarring, hernias, and allergic predisposition are common. SMAD3 is more frequently associated with early-onset osteoarthritis, while some forms related to TGFB2 may manifest later or present with fewer syndromic features.
Disease management
Currently, there is no curative treatment. Management requires lifelong vascular surveillance with echocardiography and head-to-pelvis MR angiography or CT angiography. Beta-blockers or angiotensin II receptor antagonists may reduce hemodynamic stress, although specific comparative trials are lacking. Preventive surgery may be indicated at smaller diameters than in other aortopathies. Systemic complications receive symptomatic treatment and pregnancy requires specialized monitoring.
Genes analyzed
Bibliography
Loeys BL, Dietz HC. Loeys-Dietz Syndrome. GeneReviews®. Updated 2024.
MacCarrick G, Afifi RO, Allen R, et al. Loeys-Dietz syndrome: 2026 updated care management primer. Genet Med. 2026;28(7):102577.
Gouda P, Kay R, Habib M, et al. Clinical features and complications of Loeys-Dietz syndrome: A systematic review. Int J Cardiol. 2022;362:158-167.
Schepers D, Tortora G, Morisaki H, et al. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3. Hum Mutat. 2018;39(5):621-634.
